Can brain lesions contribute to criminal behavior?

Jacqueline Mitchell 617-667-7306, jsmitche@bidmc.harvard.edu

DECEMBER 18, 2017

BOSTON – New research published in the Proceedings of the National Academy of Sciences indicates that lesions to brain areas in individuals exhibiting criminal behavior all fall within a particular brain network involved in moral decision-making. Previous studies have shown that the brains of some criminals exhibit abnormalities, but in most cases, it is unclear whether these abnormalities are the cause of, effect of, or simply coincide with criminality.

“Our lab has developed a new technique for understanding neuropsychiatric symptoms based on focal brain lesions and a wiring diagram of the human brain,” said senior author Michael Fox, MD, PhD, who is the Associate Director of the Deep Brain Stimulation Program at Beth Israel Deaconess Medical Center (BIDMC) “We’ve successfully applied this technique to hallucinations, delusions, involuntary movements, and coma—and in perhaps its most interesting application to date, we applied it to criminality.”

Interest in a potential link between brain lesions and criminality became especially high following the 1966 Texas Tower mass shooting carried out by Charles Whitman, who complained of headaches and personality changes prior to his killing 16 people and wounding 31 others. He was found to have a tumor in his brain, prompting the question of whether the brain injury contributed to his behavior. Lead author Richard Darby, MD, formerly of BIDMC and now assistant professor of neurology at Vanderbilt University and director of the frontotemporal dementia clinic at Vanderbilt, noted that he personally became interested in how neurological diseases might result in criminal behavior after caring for patients with frontotemporal dementia, who often commit nonviolent crimes as a result of their dementia.

To investigate the issue, Fox, Darby and their colleagues systematically mapped brain lesions in 17 patients who exhibited criminal behavior after – but not before – the lesions occurred.

Analyses revealed that the lesions were located in diverse brain regions, but all mapped to a common network. “We found that this network was involved in moral decision-making in normal people, perhaps giving a reason for why brain lesions in these locations would make patients more likely to behave criminally,” said Darby. The network is not involved with cognition control or empathy.

The findings were supported in tests of a separate group of 23 cases where the timing between brain lesions and criminal behavior was implied but not definitive. It is important to note, however, that not all individuals with brain lesions within the network identified in the study will commit crimes. Genetic, environmental, and social factors are also likely to be important. “We don’t yet know the predictive value of this approach,” said Fox, who is also an Assistant Professor of Neurology at Harvard Medical School. “For example, if a brain lesion falls outside our network, does that mean it has nothing to do with criminal behavior? Similarly, we don’t know the percentage of patients with lesions within our network who will commit crimes.”

Darby added that it is important to consider how the study’s findings should not be used. “Our results can help to understand how brain dysfunction can contribute to criminal behavior, which may serve as an important step toward prevention or even treatment,” he said. “However, the presence of a brain lesion cannot tell us whether or not we should hold someone legally responsible for their behavior. This is ultimately a question society must answer.”

Indeed, doctors, neuroscientists, lawyers and judges all struggle with criminal behavior in the setting of a brain lesion. Is the patient responsible? Should he or she be punished in the same way as people without a lesion? Is criminal behavior different than other symptoms suffered by patients after a brain lesion such as paralysis or speech trouble? “The results don’t answer these questions, but rather highlight their importance,” said Fox.

The research team included investigators from Vanderbilt University Medical Center, Charité - University Medicine, Harvard University, BIDMC, and Harvard Medical School.

This work was supported by funding from the Sidney 763 R. Baer, Jr. Foundation, the NIH (K23NS083741), the Dystonia Foundation, the Nancy Lurie Marks Foundation, the Alzheimer’s Association, and the BrightFocus Foundation.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.

BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, MetroWest Medical Center, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.